KRAS and neoplasm: In KRAS(G12C)-addicted tumor models, resistance mechanisms may involve upregulation of RTKs, alternative signaling through PI3K/AKT, and SHP2 dependence, depending on cellular context (Hallin et al., 2020; Amodio et al., 2020).